Stockscreener 앱 받기
93.63
0.10%
-0.09
시간 외 거래:
93.63
Rhythm Pharmaceuticals Inc 주식(RYTM)의 최신 뉴스
Rhythm Pharmaceuticals Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
Green Thumb Just Made an Unprecedented Move. Here's What It Means for GTBIF Investors. - The Motley Fool
RYTM: Strong HO launch, global reach, and next-gen therapies drive growth in rare obesity markets - TradingView
RYTM: Strong HO launch, robust pipeline, and next-gen therapies to address key patient needs - TradingView
Guggenheim Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $143 - 富途牛牛
Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology - marketscreener.com
Hidden hunger in rare obesity: new UK study finds severe hyperphagia missed - Stock Titan
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A Biotech Gem with 46.76% Upside Potential - DirectorsTalk Interviews
A Look At Rhythm Pharmaceuticals (RYTM) Valuation After IMCIVREE Approvals And Strong First Quarter Results - Sahm
Rhythm Pharmaceuticals, Inc. (RYTM) reports Q1 loss, tops revenue estimates - MSN
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - Yahoo Finance
RYTM Maintained by Canaccord Genuity -- Price Target Raised to $143 - GuruFocus
RYTM Technical Analysis | Trend, Signals & Chart Patterns | RHYTHM PHARMACEUTICALS INC (NASDAQ:RYTM) - ChartMill
Rhythm Pharmaceuticals Price Target Raised to $143.00/Share From $140.00 by Canaccord Genuity - Moomoo
Rhythm Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:RYTM) 2026-05-07 - Seeking Alpha
Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results - Sahm
CCORF Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $143 - Moomoo
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2026 Earnings Call Transcript - Insider Monkey
Is It Too Late To Consider Rhythm Pharmaceuticals (RYTM) After Its Recent Share Price Surge - Sahm
Rhythm Pharmaceuticals Q1 2026 Earnings: Stock Rises 8% on Imcivree Revenue BeatNews and Statistics - IndexBox
A Quick Look at Today's Ratings for Rhythm Pharmaceuticals(RYTM.US), With a Forecast Between $130 to $144 - Moomoo
Full Transcript: Rhythm Pharmaceuticals Q1 2026 Earnings Call - Sahm
Rhythm Pharmaceuticals to Participate in Bank of America Conference on May 13, 2026 - geneonline.com
Morgan Stanley Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $136 - Moomoo
Rhythm Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Rhythm CEO to speak at Bank of America healthcare conference May 13 - Stock Titan
Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference - Yahoo Finance
Rhythm Pharmaceuticals Q1 2026 slides: revenue beats on HO launch By Investing.com - Investing.com Australia
MSN Money - MSN
Why Rhythm Pharmaceuticals Stock Triumphed on Tuesday - The Motley Fool
Needham Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $130 - Moomoo
Rhythm Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance
Rhythm Pharmaceuticals (RYTM) grows Q1 2026 revenue but posts larger net loss - Stock Titan
Rhythm Pharmaceuticals Weighs Long Term IMCIVREE Data And Growth Potential - Yahoo Finance
Rhythm Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
Stifel raises Rhythm Pharmaceuticals stock price target on launch By Investing.com - Investing.com South Africa
Does EU IMCIVREE Expansion for Hypothalamic Obesity Change The Bull Case For Rhythm (RYTM)? - Sahm
Stifel raises Rhythm Pharmaceuticals stock price target on launch - Investing.com UK
Rhythm Pharmaceuticals Q1 2026 slides: revenue beats on HO launch - Investing.com
Earnings call transcript: Rhythm Pharmaceuticals Q1 2026 revenue beats forecast - Investing.com Nigeria
Rhythm Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Surpasses Q1 Estimates as U.S. Hypothalamic Obesity Launch Accelerates - ChartMill
Q1 2026 Rhythm Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Rhythm Pharmaceuticals (Nasdaq: RYTM) grows IMCIVREE sales and expands approvals - Stock Titan
Rhythm Pharmaceuticals Q1 revenue rises 84% - TradingView
Earnings Flash (RYTM) Rhythm Pharmaceuticals, Inc. Reports Q1 Revenue $60.1M, Vs. FactSet Est of $55.8M - Moomoo
Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update - The Manila Times
After FDA approval, rare-obesity drug draws 150 start forms in 6 weeks - Stock Titan
Rhythm Pharmaceuticals (RYTM) Revenue Ramp With US$201.9m TTM Loss Tests Bullish Narratives - Sahm
0.96%
0.26%
자본화:
|
볼륨(24시간):